Mission Statement, Vision, & Core Values (2026) of China Resources Double-Crane Pharmaceutical Co.,Ltd.

From a legacy spanning over 70 years to its modern footprint as a China Resources affiliate, China Resources Double‑Crane Pharmaceutical Co., Ltd. combines deep heritage with market reach-established in 1997 and integrated into China Resources in 2010-operating through 16 subsidiaries and a workforce of more than 14,000 employees to deliver intravenous solutions and therapies for cardiovascular, cerebrovascular, endocrine and pediatric care; the company's portfolio features well‑known brands such as Hypertensive No.0, GuanShuang, Tangshiping, Erxiekang, Kelisu and Yashida, distributed across hospitals, community health service stations, county hospitals and pharmacies, producing an industrial revenue of 5.37 billion RMB and signaling its drive toward a 10 billion-industry strategic objective while adhering to core values-Integrity, Pursuing Excellence, Customer Comes First, Return to Community-plus commitments to Innovation and Sustainability that shape its mission "Care for People and Promote Health."

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) - Intro

• Founded (modern entity): 1997
• Acquired by China Resources: 2010
• Listed ticker: 600062.SS
• Corporate history span: >70 years (industrial lineage)
• Subsidiaries: 16
• Employees: >14,000

• Core therapeutic areas: intravenous solutions; cardiovascular & cerebrovascular; endocrine disorders; pediatric medicines
• Key branded products: Hypertensive No.0, GuanShuang, Tangshiping, Erxiekang, Kelisu, Yashida
• Sales channels: tertiary & county hospitals, community health service stations, retail pharmacies
• Manufacturing & R&D: multiple GMP-compliant production lines and research platforms supporting formulation, sterile production and API development

• Mission: Deliver safe, effective and accessible pharmaceutical products across China's healthcare system, with emphasis on sterile products and chronic-disease therapies.
• Vision: Be a leading, innovation-driven Chinese pharma enterprise recognized for quality manufacturing and broad clinical impact.
• Core values: Patient-centricity, compliance & quality, continuous R&D investment, collaborative partnerships, operational excellence.

• Distribution footprint: Multi-tier network serving hospitals (including county-level institutions), community health service stations and pharmacies to ensure product accessibility.
• Therapeutic penetration: Strong presence in cardiovascular/cerebrovascular and endocrine therapy markets, plus substantial IV solution production capacity supporting hospital consumption.
• Brand recognition: Several legacy brands (e.g., Hypertensive No.0, GuanShuang) with established clinician and patient awareness in their segments.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) - Overview

Mission Statement: China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) is committed to 'Care for People and Promote Health,' centering its strategy and operations on improving public well‑being and expanding access to essential medicines.

Enterprise values (China Resources):

• Integrity
• Pursuing Excellence
• Customer Comes First
• Return to Community

Key 2022 operational and financial highlights:

• Industrial annual revenue: 5.37 billion RMB
• Net profit: 840 million RMB (approx. 15.6% net margin)
• Ongoing strategic target: achieving a 10 billion RMB industry-scale objective

Flagship products and therapeutic coverage:

• Hypertensive No.0 - hypertension management
• GuanShuang - cardiovascular/antianginal therapy
• Tangshiping - metabolic/endocrine support
• Erxiekang - gastrointestinal/peptic care
• Kelisu - analgesic/anti-inflammatory
• Yashida - respiratory and symptomatic relief

Sales and distribution network:

• Hospitals (tertiary and secondary)
• County hospitals and community health service stations
• Retail pharmacies and chain drugstores
• Institutional procurement and hospital group tenders

Market positioning and growth focus:

• Broad product mix spanning chronic disease management and symptomatic care
• Distribution breadth designed to ensure accessibility across urban and rural healthcare tiers
• Strategic emphasis on scaling to a 10 billion RMB industry footprint via product portfolio expansion and channel penetration

Additional company background and context: China Resources Double-Crane Pharmaceutical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) - Mission Statement

• Vision: Become an industry leader in pharmaceuticals founded on innovation, quality and reproducible clinical value.
• Strategic objective: Achieve a "10 billion" industry-scale target (RMB revenue/market footprint objective), pursued through product portfolio expansion, channel penetration and targeted M&A.
• Core values: Integrity; Pursuing Excellence; Customer Comes First; Return to Community - principles that steer governance, compliance and social responsibility programs.

• Flagship and well-known products: Hypertensive No.0, GuanShuang, Tangshiping, Erxiekang, Kelisu and Yashida - covering cardiovascular, metabolic and common chronic-disease therapy segments.
• Distribution framework: Sales network covers tertiary and secondary hospitals, community health service stations, county hospitals and retail pharmacies to ensure wide accessibility across urban and rural markets.
• Commercial focus: Balance between hospital-channel tender business and retail/pharmacy OTC presence to diversify revenue streams and strengthen brand reach.

• R&D pipeline prioritization: Increased allocation of R&D budget toward cardiovascular and metabolic therapies aligned with flagship brands to drive incremental sales and clinical differentiation.
• Channel expansion: Strengthening county and community-level penetration to convert public health demand into stable off-tender and retail revenues.
• Quality & compliance: Investment in GMP upgrades and pharmacovigilance to protect product integrity and satisfy hospital procurement standards.
• Social responsibility: Community return programs and patient affordability initiatives consistent with the company's stated value of "Return to Community."

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) - Vision Statement

• Integrity: China Resources Double-Crane maintains compliance with national regulatory standards, transparent corporate governance, and ethical supply-chain practices. Internal audit and compliance teams monitor GMP, pharmacovigilance, and anti-corruption controls to protect patient safety and investor trust.
• Pursuing Excellence: Quality metrics target >99% batch release success rates, reductions in product recalls, and continuous process improvements. Performance KPIs tie operational excellence to manufacturing yield, on-time delivery, and product stability improvements.
• Customer Comes First: The company measures customer satisfaction across hospitals, distributors, and retail channels, aiming for service-level targets (order fill rate >95%) and faster response times for product complaints and clinical inquiries.
• Return to Community: Through public-health initiatives, targeted donations, and partnerships with local health bureaus, the company directs a portion of profits to community health programs and pandemic preparedness funds.
• Innovation: Annual R&D investment (~5% of revenue) funds new molecular entities, biosimilars, and formulation optimization. The innovation pipeline emphasizes sterile injectables and high-value generics with clinical and regulatory pathways.
• Sustainability: Environmental initiatives include energy-efficiency retrofits, waste minimization, and a carbon-reduction target (30% by 2030 from 2022 baseline). The company reports on water usage, hazardous waste, and emissions as part of ESG disclosure improvement.

• Capital expenditure allocation: 60% to manufacturing modernization, 25% to R&D facilities, 15% to digital systems and logistics.
• R&D pipeline focus: sterile injectables, enhanced-release oral products, and biosimilar formulations prioritized for regulatory filings over the next 3-5 years.
• Market expansion targets: increase international revenue share from 12% to 20% within 5 years through selective partnerships and registration efforts.